Abivax (NASDAQ: ABVX) — Company Overview, News & Financial Data
Abivax focuses on developing treatments for diseases with unmet needs, particularly in immune-oncology and viral infections.
Abivax
Abivax (EPA:ABVX), (NASDAQ:ABVX) is a biotechnology firm focused on developing treatments for diseases with unmet medical needs, particularly in the areas of immune-oncology, viral infections, and inflammatory diseases. The company is recognized for its innovative research and development projects aiming to produce novel drugs that can significantly impact patients' lives across the globe. Abivax's ambitious objectives include advancing their lead compound through clinical trials, securing partnerships for broader drug distribution, and expanding their drug pipeline through cutting-edge research. With a commitment to scientific excellence and patient well-being, Abivax strives to be at the forefront of breakthrough therapies that could transform standard care practices in several therapeutic areas.
Snapshot
Operations
Products and/or services of Abivax
- ABX464 - An anti-inflammatory drug targeting HIV, Ulcerative Colitis, and Rheumatoid Arthritis.
- ABX196 - An immune enhancer for Hepatocellular Carcinoma in combination with nivolumab.
- ABX544 - A therapeutic vaccine candidate aimed at preventing and treating Ebola virus infections.
- COVID-19 program - Developing treatments to combat the SARS-CoV-2 virus, leveraging their immune system modulating technology.
- ABX1103 - An anti-inflammatory molecule focused on targeting chronic inflammatory diseases beyond the company's existing portfolio.
- ABX1032 - A novel antiviral therapy aimed at treating a range of viral infections with high unmet medical need.
Abivax executive team
- Marc M. P. de GaridelCEO & Director
- Didier BlondelEVP, CFO & Board Secretary
- Timothy P. KellyChief Technical Officer
- Patrick MalloySenior VP & Head of Investor Relations
- Ida HatoumChief People & Compliance Officer
- James BergerGlobal Head of Marketing
- Pierre CourteilleChief Business Officer
- Jerome DenisExecutive Vice President of Process Development & Manufacturing
- Hema KeshavaSenior Vice President of Finance
- Chris RabbatChief Medical Officer
Key financials
Reported results for Abivax , in EUR.
- Market cap
- 7.4B
- Revenue (TTM)
- 4.7M
- P/E ratio
- —
- EPS (diluted, TTM)
- -6.1
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 0 | -246.1M | -336.1M | |
| 10.8M | -173M | -176.2M | |
| 4.6M | -127.4M | -147.7M | |
| 4.6M | -64.8M | -60.7M |